• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

他汀类药物治疗家族性高胆固醇血症的疗效:一项长期队列研究。

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.

作者信息

Versmissen Jorie, Oosterveer Daniëlla M, Yazdanpanah Mojgan, Defesche Joep C, Basart Dick C G, Liem Anho H, Heeringa Jan, Witteman Jacqueline C, Lansberg Peter J, Kastelein John J P, Sijbrands Eric J G

机构信息

Department of Internal Medicine, Erasmus University Medical Centre, PO box 2040, 3000 CA Rotterdam, Netherlands.

出版信息

BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423.

DOI:10.1136/bmj.a2423
PMID:19001495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2583391/
Abstract

OBJECTIVE

To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia.

DESIGN

Cohort study with a mean follow-up of 8.5 years.

SETTING

27 outpatient lipid clinics.

SUBJECTS

2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990.

MAIN OUTCOME MEASURES

Risk of coronary heart disease in treated and "untreated" (delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable.

RESULTS

In January 1990, 413 (21%) of the patients had started statin treatment, and during follow-up another 1294 patients (66%) started after a mean delay of 4.3 years. Most patients received simvastatin (n=1167, 33 mg daily) or atorvastatin (n=211, 49 mg daily). We observed an overall risk reduction of 76% (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), P=0.23).

CONCLUSION

Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population.

摘要

目的

确定他汀类药物治疗对家族性高胆固醇血症患者冠心病风险的疗效。

设计

平均随访8.5年的队列研究。

地点

27家门诊脂质诊所。

研究对象

1990年1月1日前无冠心病史的2146例家族性高胆固醇血症患者。

主要观察指标

将接受治疗和“未治疗”(延迟开始他汀类药物治疗)的患者的冠心病风险与他汀类药物使用作为时间依赖性变量的Cox回归模型进行比较。

结果

1990年1月,413例(21%)患者开始他汀类药物治疗,随访期间另有1294例患者(66%)平均延迟4.3年后开始治疗。大多数患者接受辛伐他汀(n = 1167,每日33毫克)或阿托伐他汀(n = 211,每日49毫克)治疗。我们观察到总体风险降低了76%(风险比0.24(95%置信区间0.18至0.30),P < 0.001)。事实上,这些接受他汀类药物治疗的患者发生心肌梗死的风险并不显著高于来自普通人群的年龄匹配样本(风险比1.44(0.80至2.60),P = 0.23)。

结论

与目前建议的剂量相比,较低剂量的他汀类药物在家族性高胆固醇血症患者中降低冠心病风险的程度比预期更大。使用他汀类药物治疗后,这类患者发生心肌梗死的风险与普通人群无显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/771fa83fc2ae/verj594622.f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/db79bcb096b1/verj594622.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/7812d2daeb7d/verj594622.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/e260e696921a/verj594622.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/771fa83fc2ae/verj594622.f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/db79bcb096b1/verj594622.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/7812d2daeb7d/verj594622.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/e260e696921a/verj594622.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c20/4787069/771fa83fc2ae/verj594622.f4.jpg

相似文献

1
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.他汀类药物治疗家族性高胆固醇血症的疗效:一项长期队列研究。
BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423.
2
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.高剂量阿托伐他汀在预防外周动脉疾病方面优于中等剂量辛伐他汀。
Heart. 2015 Mar;101(5):356-62. doi: 10.1136/heartjnl-2014-306906. Epub 2015 Jan 16.
3
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial).急性心肌梗死后晚期(五年)心血管事件发生频率:阿托伐他汀每日80毫克与辛伐他汀每日20至40毫克的比较(来自通过积极降脂减少终点事件[IDEAL]试验)
Am J Cardiol. 2010 Aug 1;106(3):354-9. doi: 10.1016/j.amjcard.2010.03.033.
4
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.阿托伐他汀治疗期间心血管事件减少与新发糖尿病:糖尿病基线风险因素的影响。
J Am Coll Cardiol. 2013 Jan 15;61(2):148-52. doi: 10.1016/j.jacc.2012.09.042. Epub 2012 Dec 5.
5
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.阿托伐他汀和辛伐他汀在有和无既往心血管疾病患者中的持续性:一项美国管理式医疗研究。
Curr Med Res Opin. 2008 Jul;24(7):1987-2000. doi: 10.1185/03007990802203279. Epub 2008 Jun 4.
6
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.家族性高胆固醇血症患者血清可溶性CD40配体水平升高:他汀类药物治疗的下调作用
J Am Coll Cardiol. 2003 Jan 15;41(2):275-9. doi: 10.1016/s0735-1097(02)02718-3.
7
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.高剂量阿托伐他汀治疗重度杂合子家族性高胆固醇血症
QJM. 1998 Apr;91(4):291-4. doi: 10.1093/qjmed/91.4.291.
8
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.大剂量阿托伐他汀在 ST 段抬高型心肌梗死患者直接经皮冠状动脉介入治疗前的疗效:STIN 试验。
JACC Cardiovasc Interv. 2010 Mar;3(3):332-9. doi: 10.1016/j.jcin.2009.11.021.
9
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.细胞色素P450 3A4代谢的他汀类药物对600毫克负荷剂量氯吡格雷抗血小板作用及择期冠状动脉支架置入患者临床结局的影响。
Thromb Haemost. 2008 Jan;99(1):174-81. doi: 10.1160/TH07-08-0503.
10
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.高剂量阿托伐他汀与常规剂量辛伐他汀用于心肌梗死后二级预防:IDEAL研究:一项随机对照试验。
JAMA. 2005 Nov 16;294(19):2437-45. doi: 10.1001/jama.294.19.2437.

引用本文的文献

1
Familial Hypercholesterolemia: Still an Enigma.家族性高胆固醇血症:仍是一个谜。
JACC Case Rep. 2025 Aug 27;30(25):104755. doi: 10.1016/j.jaccas.2025.104755.
2
Pediatric Familial Hypercholesterolemia: Targeting Intestinal Absorption and Other Therapeutic Strategies.小儿家族性高胆固醇血症:针对肠道吸收及其他治疗策略
Nutrients. 2025 Jul 18;17(14):2357. doi: 10.3390/nu17142357.
3
Role of Next-Generation Sequencing in Diagnosis of Familial Hypercholesterolemia in Serbia.下一代测序在塞尔维亚家族性高胆固醇血症诊断中的作用

本文引用的文献

1
Lipid screening and cardiovascular health in childhood.儿童期血脂筛查与心血管健康
Pediatrics. 2008 Jul;122(1):198-208. doi: 10.1542/peds.2008-1349.
2
Simvastatin with or without ezetimibe in familial hypercholesterolemia.辛伐他汀联合或不联合依折麦布治疗家族性高胆固醇血症
N Engl J Med. 2008 Apr 3;358(14):1431-43. doi: 10.1056/NEJMoa0800742. Epub 2008 Mar 30.
3
Statin treatment in children with familial hypercholesterolemia: the younger, the better.家族性高胆固醇血症患儿的他汀类药物治疗:年龄越小,效果越好。
Diagnostics (Basel). 2025 May 12;15(10):1212. doi: 10.3390/diagnostics15101212.
4
Evaluation of glycemic status and subclinical atherosclerosis in familial hypercholesterolemia subjects with or without LDL receptor mutation.对伴有或不伴有低密度脂蛋白受体突变的家族性高胆固醇血症患者的血糖状态和亚临床动脉粥样硬化的评估。
Cardiovasc Diabetol. 2025 Mar 20;24(1):126. doi: 10.1186/s12933-025-02683-y.
5
Cost-effectiveness of universal genetic screening for familial hypercholesterolemia in young adults aged 18-40 years in China.中国18至40岁年轻成年人中家族性高胆固醇血症普遍基因筛查的成本效益
BMC Med. 2025 Mar 5;23(1):139. doi: 10.1186/s12916-025-03966-7.
6
A Scoping Review of Electronic Health Records-Based Screening Algorithms for Familial Hypercholesterolemia.基于电子健康记录的家族性高胆固醇血症筛查算法的范围综述
JACC Adv. 2024 Oct 16;3(12):101297. doi: 10.1016/j.jacadv.2024.101297. eCollection 2024 Dec.
7
Naringenin modulates oxidative stress and lipid metabolism: Insights from network pharmacology, mendelian randomization, and molecular docking.柚皮素调节氧化应激和脂质代谢:来自网络药理学、孟德尔随机化和分子对接的见解
Front Pharmacol. 2024 Oct 15;15:1448308. doi: 10.3389/fphar.2024.1448308. eCollection 2024.
8
Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations.对来自不同人群的1,158,017名个体进行血脂外显子组全关联研究。
medRxiv. 2024 Sep 18:2024.09.17.24313718. doi: 10.1101/2024.09.17.24313718.
9
Synthesized economic evidence on the cost-effectiveness of screening familial hypercholesterolemia.家族性高胆固醇血症筛查的成本效益综合经济学证据。
Glob Health Res Policy. 2024 Sep 26;9(1):38. doi: 10.1186/s41256-024-00382-x.
10
Familial Hypercholesterolemia: Pitfalls and Challenges in Diagnosis and Treatment.家族性高胆固醇血症:诊断与治疗中的陷阱和挑战
Rev Cardiovasc Med. 2023 Aug 17;24(8):236. doi: 10.31083/j.rcm2408236. eCollection 2023 Aug.
Circulation. 2007 Aug 7;116(6):664-8. doi: 10.1161/CIRCULATIONAHA.106.671016. Epub 2007 Jul 30.
4
Are lipid-lowering guidelines evidence-based?降脂指南是基于证据的吗?
Lancet. 2007 Jan 20;369(9557):168-9. doi: 10.1016/S0140-6736(07)60084-1.
5
Guidelines were developed for data collection from medical records for use in retrospective analyses.制定了从医疗记录中收集数据用于回顾性分析的指南。
J Clin Epidemiol. 2005 Mar;58(3):269-74. doi: 10.1016/j.jclinepi.2004.07.006.
6
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.大剂量阿托伐他汀治疗家族性高胆固醇血症患者的长期安全性和疗效。
Am J Cardiol. 2005 Jan 15;95(2):264-6. doi: 10.1016/j.amjcard.2004.09.015.
7
The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients.经典危险因素对家族性高胆固醇血症患者心血管疾病的影响:2400例患者的数据
J Intern Med. 2004 Dec;256(6):482-90. doi: 10.1111/j.1365-2796.2004.01405.x.
8
Familial hypercholesterolemia and coronary heart disease: a HuGE association review.家族性高胆固醇血症与冠心病:一项HuGE关联研究综述
Am J Epidemiol. 2004 Sep 1;160(5):421-9. doi: 10.1093/aje/kwh237.
9
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.他汀类药物治疗家族性高胆固醇血症儿童的疗效和安全性:一项随机对照试验。
JAMA. 2004 Jul 21;292(3):331-7. doi: 10.1001/jama.292.3.331.
10
Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia.接受他汀类药物治疗的家族性高胆固醇血症患者的心血管疾病与死亡率
Atherosclerosis. 2004 Feb;172(2):329-35. doi: 10.1016/j.atherosclerosis.2003.11.007.